References
- Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, et al. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Indian J Cancer. 2018;55(1):50–54. doi:https://doi.org/10.4103/ijc.IJC_468_17.
- Bois AD, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d’Investigateurs nationaux pour les etudes des cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–1244. doi:https://doi.org/10.1002/cncr.24149.
- Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol. 2004;93(3):699–701. doi:https://doi.org/10.1016/j.ygyno.2004.03.023.
- Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–2612. doi:https://doi.org/10.1093/annonc/mds203.
- Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives–a review. J Ovarian Res. 2019;12(1):103. doi:https://doi.org/10.1186/s13048-019-0579-0.
- Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, et al. Current ovarian cancer maintenance strategies and promising new developments. J Cancer. 2021;12(1):38–53. doi:https://doi.org/10.7150/jca.494.
- Foo T, George A, Banerjee S. PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. Genes Chromosomes Cancer. 2021;60(5):385–97. doi:https://doi.org/10.1002/gcc.22935.
- Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. doi:https://doi.org/10.1136/bmj.m3773.
- Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020;16(7):225–246. doi:https://doi.org/10.2217/fon-2019-0042.
- Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761–5766. doi:https://doi.org/10.1200/JCO.2008.17.0282.
- Sehouli J, Alvarez AM, Manouchehrpour S, Ghatage P, Szczylik C, Zimmermann A, et al. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2012;124(2):205–209. doi:https://doi.org/10.1016/j.ygyno.2011.09.007.
- Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686–2691. doi:https://doi.org/10.1200/JCO.2008.19.2963.
- Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, et al. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2013;131(3):535–540. doi:https://doi.org/10.1016/j.ygyno.2013.09.032.
- Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban González E, Martín Algarra S. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol. 2009;11(1):35–40. doi:https://doi.org/10.1007/s12094-009-0308-z.
- Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005;104(11):2449–2456. doi:https://doi.org/10.1002/cncr.21480.
- Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255. doi:https://doi.org/10.1016/S1470-2045(12)70063-3.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. JCO. 2003;21(14):2636–2644. doi:https://doi.org/10.1200/JCO.2003.11.136.
- Pandey A, Abhay D, Sunny J, Vikas O, Vijay P, Rajeshri K, et al. Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: an Indian rural cancer centre experience. South Asian J Cancer. 2016;5(2):59–62. doi:https://doi.org/10.4103/2278-330X.181627.
- Gulia S, Ghosh J, Bajpai J, Rath S, Maheshwari A, Shylasree TS, et al. Pazopanib and oral cyclophosphamide in women with platinum-resistant or -refractory epithelial ovarian cancer. JCO Glob Oncol. 2020;6:542–547. doi:https://doi.org/10.1200/JGO.19.00331.
- Sharma A, Malik PS, Khurana S, Kumar S, Bhatla N, Ray MD, et al. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: a retrospective analysis. Indian J Med Res. 2019;150(6):575–583. doi:https://doi.org/10.4103/ijmr.IJMR_2030_18.
- Pfisterer J, Plante M, Vergote I, Du Bois A, Hirte H, Lacave AJ, EORTC GCG, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–4707. doi:https://doi.org/10.1200/JCO.2006.06.0913.
- Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–16. doi:https://doi.org/10.1016/j.ygyno.2015.08.004.
- Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. JCO. 2010;28(20):3323–3329. doi:https://doi.org/10.1200/JCO.2009.25.7519.
- Icon T, Collaborators AGO. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106. doi:https://doi.org/10.1016/S0140-6736(03)13718-X.
- Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomized, open-label, phase 3 trial. Lancet Oncol. 2020;21(5):699–709. doi:https://doi.org/10.1016/S1470-2045(20)30142-X.
- Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009;45(8):1415–1423. doi:https://doi.org/10.1016/j.ejca.2008.12.013.